

January 27, 2021

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

To
The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANLAB; Series: EQ



Dear Sirs,

Results Release and Earnings Call Notice

We refer to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015 and enclose a copy of the Q3 FY 2020-2021 Earnings Call details, for your information and records.

Thanking you,

Yours faithfully,
For Neuland Laboratories Limited



Sarada Bhamidipati
Company Secretary

Encl: As above

Neuland Laboratories Limited's Q3FY21 Results Conference Call At 17:00 hrs. IST on February 2, 2021

Neuland Laboratories Limited will announce its results for the third quarter and nine months ended December 31, 2020 on February 2, 2021. The results will also be made available on the website of the Company, www.neulandlabs.com

Following the announcement, the management of the Company will host an Earnings Call on the **2 February at 17:00 hrs.** The details of the earnings call are:

Date: February 2, 2021

Time: 17:00 Hrs

Dial-in Numbers:

+91 22 6280 1107 / +91 22 7115 8008

For Diamond Pass Please Click Here:

[Diamond Pass](#)

Local Access Number: +91 70456 71221 (Available all over India)

International Toll-Free Number: USA - 18667462133 | UK - 08081011573 | Singapore - 8001012045 | Hong Kong - 800964448

About Neuland Laboratories Limited (BSE:524558, NSE: NEULANLAB)

For over 37 years, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 75 APIs and has filed over 898+ Regulatory filings in the US (57 active US DMFs), the European Union (EU) and other geographies. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID &GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001.

For more information, visit www.NeulandLabs.com.

For more queries please contact:

Neuland: ir@neulandlabs.com OR

Diwakar Pingle: dpingle@christensenir.com